Srigita Madiraju

ORCID: 0009-0002-2570-3610
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Metabolism and Genetic Disorders
  • Healthcare Policy and Management
  • Sarcoma Diagnosis and Treatment
  • Global Health and Surgery
  • Vascular Tumors and Angiosarcomas
  • Urinary and Genital Oncology Studies
  • Cardiac tumors and thrombi
  • Renal cell carcinoma treatment
  • Bladder and Urothelial Cancer Treatments

University of Toledo
2023-2024

Background: Access to surgical equipment is critical providing safe and equitable operative care. This the first nationwide study provide data on availability of in Kenya. Methods: cross-sectional collected from May July 2018 non-pharmaceutical equipment, patient care, intra-operative, anesthesia supplies level 4 hospitals. Information regarding infrastructure such as number functional operating rooms, sterilization capacity, sources water electricity was also collected. Results: The...

10.4314/aas.v22i1.2 article EN cc-by Annals of African Surgery 2025-02-19

A 71-year-old male with benign prostatic hyperplasia managed by self-catheterization presented gross hematuria. CT scan of abdomen and pelvis demonstrated abnormal bladder appearance right sided mass a diverticulum. Patient underwent transurethral resection tumor. Pathology was significant for high-grade muscle-invasive angiosarcoma. The malignant cells showed positive staining vimentin CD31. Given patient's underlying comorbidities following multidisciplinary discussion, hospice care...

10.1016/j.eucr.2023.102593 article EN cc-by-nc-nd Urology Case Reports 2023-10-17

Allosensitization (PRA+) has been reported after discontinuation of immunosuppression (IS) following graft failure (GF) in islet transplant (ITx) recipients. Persistence PRA+ GF is unknown. Thirteen ITx alone (IA) and 5 subjects who also received donor CD34+ hematopoietic stem cells (IBM) developed enrolled the study “Allosensitization After Islet Transplantation.” Panel reactive antibodies (PRA) were measured yearly while having function, within 1 year post-GF enrollment. Two but remained...

10.2337/db18-142-or article EN Diabetes 2018-06-22
Coming Soon ...